Disease status at study enrollment and disease responses during study
. | . | . | Outcome, months after allo . | . | |
|---|---|---|---|---|---|
| At time of auto, n = 54 . | After auto, n = 54 . | Best after allo, n = 52 . | Deceased, mo/cause n = 12 . | Alive, mo, n = 42 . | |
| 6 CR | 6 CR | 6 CR | 3/enceph, 7/cGVHD | 18, 20, 24R, 24 | |
| 22 PR | 5 CR | 5 CR | — | 13, 19, 20, 24, 27R | |
| 11 PR | 6 CR | — | 12, 12, 13, 20, 24, 37 | ||
| 5 PR | — | 7, 12, 13, 18, 24 | |||
| 6 SD | 3 CR | — | 12, 12, 13 | ||
| 1 PR | 14/pulmonary cGVHD | — | |||
| 2 SD | — | 9, 18 | |||
| 7 REL | 0 CR | — | — | — | |
| 1 PR | 1 PR | 6/GVHD | — | ||
| 6 SD | 1 CR | 37/GVHD | — | ||
| 3 PR | 14/lung Cancer | 19, 19 | |||
| 2 PD | 23/MM | 19 | |||
| 19 REF | 0 CR | — | — | — | |
| 8 PR | 6 CR | — | 12, 18, 18, 18R, 20, 31 | ||
| 2 PR | 13/GVHD | 13 | |||
| 6 SD | 3 CR | — | 18, 36, 36 | ||
| 1 PR | 10R/GVHD | — | |||
| 2 SD | 3/GVHD | 6 | |||
| 3 PD | 1 CR | — | 17 | ||
| 1 PR | — | 12 | |||
| 1 PD | 3/MM | — | |||
| 2 NE | 2 NE | CMV after auto | 1 alive no allo | ||
. | . | . | Outcome, months after allo . | . | |
|---|---|---|---|---|---|
| At time of auto, n = 54 . | After auto, n = 54 . | Best after allo, n = 52 . | Deceased, mo/cause n = 12 . | Alive, mo, n = 42 . | |
| 6 CR | 6 CR | 6 CR | 3/enceph, 7/cGVHD | 18, 20, 24R, 24 | |
| 22 PR | 5 CR | 5 CR | — | 13, 19, 20, 24, 27R | |
| 11 PR | 6 CR | — | 12, 12, 13, 20, 24, 37 | ||
| 5 PR | — | 7, 12, 13, 18, 24 | |||
| 6 SD | 3 CR | — | 12, 12, 13 | ||
| 1 PR | 14/pulmonary cGVHD | — | |||
| 2 SD | — | 9, 18 | |||
| 7 REL | 0 CR | — | — | — | |
| 1 PR | 1 PR | 6/GVHD | — | ||
| 6 SD | 1 CR | 37/GVHD | — | ||
| 3 PR | 14/lung Cancer | 19, 19 | |||
| 2 PD | 23/MM | 19 | |||
| 19 REF | 0 CR | — | — | — | |
| 8 PR | 6 CR | — | 12, 18, 18, 18R, 20, 31 | ||
| 2 PR | 13/GVHD | 13 | |||
| 6 SD | 3 CR | — | 18, 36, 36 | ||
| 1 PR | 10R/GVHD | — | |||
| 2 SD | 3/GVHD | 6 | |||
| 3 PD | 1 CR | — | 17 | ||
| 1 PR | — | 12 | |||
| 1 PD | 3/MM | — | |||
| 2 NE | 2 NE | CMV after auto | 1 alive no allo | ||
CR indicates complete remission; enceph, encephalopathy; cGVHD, chronic graft-versus-host disease; —, no data necessary; R, relapse; PR, partial remission; SD, stable disease; REL, untested relapsed disease; PD, progression of disease; MM, multiple myeloma; REF, refractory disease; and NE, not evaluable.